Royal Bank of Canada’s Lucid Diagnostics LUCD Stock Holding History

Royal Bank of Canada’s Portfolio LUCD Stock Details LUCD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9K	Sell	7,907 -2,433	-24%	-$3.1K	﹤0.01%	6210
2025 Q4	$11K	Buy	10,340 +5,247	+103%	+$5.87K	﹤0.01%	6365
2025 Q3	$5K	Buy	5,093 +2,594	+104%	+$2.83K	﹤0.01%	6702
2025 Q2	$2K	Buy	+2,499	New	+$3.23K	﹤0.01%	6805
2024 Q3	–	Sell	-196	Closed	–	–	7177
2024 Q2	$0	Buy	196 +107	+120%	+$91	﹤0.01%	7334
2024 Q1	$0	Sell	89 -109	-55%	-$141	﹤0.01%	7337
2023 Q4	$0	Buy	+198	New	+$261	﹤0.01%	7379
2023 Q3	–	Sell	-95	Closed	–	–	7354
2023 Q2	$0	Buy	+95	New	+$143	﹤0.01%	7474
2022 Q2	–	Sell	-910	Closed	-$3K	–	7565
2022 Q1	$3K	Sell	910 -764	-46%	-$2.79K	﹤0.01%	7389
2021 Q4	$9K	Buy	+1,674	New	+$13.6K	﹤0.01%	7083

Other funds holding LUCD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MCM

Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

Royal Bank of Canada's LUCD Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lucid Diagnostics (LUCD) stake by 24% in Q1 2026, selling an estimated $3.1K and leaving 7,907 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #6210.

Royal Bank of Canada first reported a position in LUCD in Q4 2021 and has held it in 10 quarters since. The position peaked at $11K in Q4 2025. 103 funds tracked by Wall St. Rank hold LUCD as of Q1 2026.

Royal Bank of Canada held 7,907 shares of Lucid Diagnostics worth $9K as of Q1 2026.
Royal Bank of Canada sold 2,433 Lucid Diagnostics shares in Q1 2026, an estimated $3.1K.
Lucid Diagnostics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6210 holding.
Royal Bank of Canada first reported a position in Lucid Diagnostics in Q4 2021 and has held it in 10 quarters since.
Royal Bank of Canada's Lucid Diagnostics position peaked at $11K in Q4 2025.
103 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.